Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mirco Castoldi has a total of 151 co-authors. Here are the top co-authors by number of shared publications:

  • Tom Luedde

    Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Duesseldorf, Medical Faculty at Heinrich-Heine-University, 40225 Dusseldorf, Germany

    7 shared publications
  • Christoph Roderburg

    Department of Gastroenterology, Hepatology and Infectious Diseases, Medical Faculty, Heinrich Heine University Düsseldorf, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Düsseldorf, Germany

    3 shared publications
  • Lara R. Heij

    Department of Surgery and Transplantation, University Hospital RWTH Aachen, Aachen, Germany; Department of Surgery and Transplantation, University Hospital Essen, Essen, Germany; Department of Pathology, Erasmus Medical Center Rotterdam, The Netherlands

    3 shared publications
  • Michael T. Singer

    Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Düsseldorf, Medical Faculty at Heinrich-Heine-University, Duesseldorf, Germany

    3 shared publications
  • Mihael Vucur

    Department of Gastroenterology, Hepatology and Infectious Diseases, Medical Faculty, Heinrich Heine University Düsseldorf, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Düsseldorf, Germany

    3 shared publications
  • Rossella Pellegrino

    Institute of Pathology, University Hospital Heidelberg, 69120 Heidelberg, Germany

    3 shared publications

Latest Publications

  • Open Access

    The Biological Limits of microRNA Therapeutics: Lessons from Preclinical and Clinical Studies

    by Mirco Castoldi

    MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression through post-transcriptional gene silencing. Since their discovery, miRNAs have emerged as key regulators of numerous biological processes and have been implicated in a wide range of human diseases, including liver cancer. Altered miRNA expression profiles have been associated with disease initiation, progression, therapeutic response, and clinical outcome, including in chronic liver diseases and hepatocellular carcinoma, where numerous dysregulated miRNAs have been proposed as therapeutic targets. Consequently, considerable efforts have focused on restoring downregulated tumor suppressor miRNAs using synthetic mimics or inhibiting oncogenic miRNAs with antisense oligonucleotides and related technologies. Despite encouraging preclinical results and substantial investment over the past two decades, the clinical translation of miRNA-based therapeutics has remained limited.In this review, we examine the biological and translational challenges that inherently limit therapeutic modulation of miRNAs in vivo. We discuss how the broad regulatory scope of individual miRNAs, their extensive target networks, context-dependent functions, functional redundancy, and the difficulty of achieving physiologically relevant modulation contribute to unpredictable therapeutic outcomes. Collectively, the available data suggests that although miRNAs remain invaluable biomarkers and powerful tools for understanding disease biology, the very biological properties that make them attractive regulators of cellular processes also represent fundamental challenges to their successful therapeutic application.

  • Open Access

    Identification of Proliferation-Specific Dependencies for Therapeutic Targeting of Liver Cancer

    by Mirco Castoldi

    Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide despite recent therapeutic advances, driven in part by its marked etiological and molecular heterogeneity and the lack of broadly effective therapeutic targets. Identifying conserved tumor dependencies shared across distinct etiological backgrounds may provide new opportunities for targeted therapy. Here, we developed an integrative computational framework to systematically integrate transcriptomic, functional genomics, and clinical datasets for the identification and prioritization of candidate tumor dependency genes in liver cancer. We reanalyzed transcriptomic data from murine models of liver cancer driven by genotoxic (DEN), oncogenic (c-Myc), and inflammatory (lymphotoxin) stimuli, identifying more than 380 genes consistently upregulated across all tumor models. Functional enrichment analysis revealed a strong overrepresentation of cell cycle-related pathways and liver cancer signatures. Integration with DepMap dependency datasets identified 26 genes with strong dependency scores. Candidate genes were further prioritized by comparing their expression across models of liver regeneration, chronic liver injury, and liver cancer. Analysis of the TCGA-LIHC cohort confirmed significant overexpression of all 26 genes in human HCC, with high expression associated with poor patient survival. Together, these findings establish an integrative framework for identifying conserved tumor dependencies, providing a prioritized set of proliferation-associated genes for functional evaluation as therapeutic targets in HCC.

  • Open Access

    qLOOK: A Minimal Information System for Digital Storage and Reproducible Analysis of qPCR experiments

    by Mirco Castoldi

    Objective: Quantitative real-time PCR is widely used for gene expression analysis, yet inconsistencies in data storage and reporting limit reproducibility. While MIQE guidelines define the minimal information required for publication, they do not specify structured digital storage formats compatible with long-term reanalysis. This work presents qLOOK (qPCR-LOg-boOK), a tool for standardized digital storage and reproducible analysis of qPCR experiments. Results: qLOOK is a modular R-based system that extracts data from Thermo Fisher/ABI .EDS files, formats it into a structured table (qLOOK_Data.xlsx), performs normalization and statistical analysis, and generates a log file (qLOOK_Summary.txt) recording reference genes, calibrators, and analytical parameters. All required R libraries are automatically installed and loaded, allowing researchers without coding experience to use the scripts. By preserving the qLOOK_Data table and the qLOOK_Summary log, users can reproduce or extend analyses without reprocessing raw files. While currently limited to .EDS files, the modular design allows adaptation to additional qPCR formats in the future. Besides providing an easy and transparent approach to analyze qPCR experiments, qLOOK also provides a minimal, standardized, and transparent solution for digital documentation, enhancing reproducibility, supporting long-term data stewardship, and facilitating integration into electronic laboratory notebooks or publication supplementary material.

  • Open Access

    A decision point between transdifferentiation and programmed cell death priming controls KRAS-dependent pancreatic cancer development

    by Anne T. Schneider, Christiane Koppe, Emilie Crouchet, Aristeidis Papargyriou, Michael T. Singer, Veronika Büttner, Leonie Keysberg, Marta Szydlowska, Frank Jühling, Julien Moehlin, et al.

    KRAS-dependent acinar-to-ductal metaplasia (ADM) is a fundamental step in the development of pancreatic ductal adenocarcinoma (PDAC), but the involvement of cell death pathways remains unclear. Here, we show that key regulators of programmed cell death (PCD) become upregulated during KRAS-driven ADM, thereby priming transdifferentiated cells to death. Using transgenic mice and primary cell and organoid cultures, we show that transforming growth factor (TGF)-β-activated kinase 1 (TAK1), a kinase regulating cell survival and inflammatory pathways, prevents the elimination of transdifferentiated cells through receptor-interacting protein kinase 1 (RIPK1)-mediated apoptosis and necroptosis, enabling PDAC development. Accordingly, pharmacological inhibition of TAK1 induces PCD in patient-derived PDAC organoids. Importantly, cell death induction via TAK1 inhibition does not appear to elicit an overt injury-associated inflammatory response. Collectively, these findings suggest that TAK1 supports cellular plasticity by suppressing spontaneous PCD activation during ADM, representing a promising pharmacological target for the prevention and treatment of PDAC.


  • Open Access

    Regulation of KIF23 by miR-107 controls replicative tumor cell fitness in mouse and human hepatocellular carcinoma

    by Mirco Castoldi, Sanchari Roy, Carolin Angendohr, Rossella Pellegrino, Mihael Vucur, Michael T. Singer, Veronika Buettner, Matthias A. Dille, Stephanie D. Wolf, Lara R. Heij, et al.


  • Open Access

    KIF23 regulation by miR-107 controls replicative tumor cell fitness in mouse and human hepatocellular carcinoma

    by Mirco Castoldi, Sanchari Roy, Carolin Lohr, Rossella Pellegrino, Mihael Vucur, Michael T. Singer, Veronika Buettner, Matthias A. Dille, Lara R. Heij, Lars Zender, et al.

    Background & Aims: In hepatocellular carcinoma, there is a lack of successful translation of experimental targets identified in mouse models to human patients. In this study, we used a comprehensive transcriptomic approach in mice to identify novel potential targets for therapeutic intervention in humans. Methods: We analysed combined genome-wide miRNA and mRNA expression data in three pathogenically distinct mouse models of liver cancer. Effects of target genes on hepatoma cell fitness were evaluated by proliferation, survival and motility assays. TCGA and GEO databases, in combination with tissue microarrays (TMA), were used to validate the mouse targets and their impact on human HCC prognosis. Finally, the functional effects of the identified targets on tumorigenesis and tumor therapy were tested in hydrodynamic tail vein injection (HDTVi)-based preclinical HCC models in vivo . Results: The expression of miR-107 was found to be significantly reduced in mouse models of liver tumors of various etiologies and in cohorts of human HCC patients. Overexpression of miR-107 or inhibition of its novel target Kinesin family member 23 (Kif23) significantly reduced proliferation by interfering with cytokinesis, thereby controlling survival and motility of mouse and human hepatoma cells. In humans, KIF23 expression was found to be a prognostic marker in liver cancer, with high expression associated with poor prognosis. HDTVi of vectors carrying either pre-miR- 107 or anti-Kif23 shRNA inhibited the development of highly aggressive cMyc-NRas- induced liver cancers in mice. Conclusions: Disruption of the miR-107/Kif23 axis inhibited hepatoma cell proliferation in vitro and prevented oncogene-induced liver cancer development in vivo , offering a novel potential avenue for the treatment of HCC in humans. Impact and implications: A comprehensive analysis integrating in silico prediction, miRNA and mRNA data in three pathogenically distinct mouse models provided novel targets for the treatment of human HCC, bridging the translational gap between mouse data and human HCC. Our functional findings on the novel miR-107/Kif23 module provide important new insights into the control of mitosis in liver cancer cells. The findings that miR-107 overexpression or Kif23 inhibition had a dramatic functional effect on inhibiting the growth of liver cancer cells in vitro and in vivo suggest that the miR-107/Kif23 axis may be a promising novel target and potential adjunct to sequential systemic therapy of HCC. Graphical Highlights: miR-107 is globally downregulated in mouse liver cancers of different etiologies and represents a potential biomarker in human HCC. Integration of in-silico -prediction, miRNA and mRNA transcriptomics identified KIF23, a mitotic spindle-associated protein, as a specific target mediating the biological effects of miR-107. The miR-107/KIF23 module promotes replicative fitness of liver cancer cells through an essential function in cytokinesis Mice receiving shRNA targeting Kif23 were completely protected from oncogene-induced liver cancer.

  • Open Access

    Uncovering Novel Roles of miR-122 in the Pathophysiology of the Liver: Potential Interaction with NRF1 and E2F4 Signaling

    by Martha Paluschinski, Jessica Schira-Heinen, Rossella Pellegrino, Lara R. Heij, Jan Bednarsch, Ulf P. Neumann, Thomas Longerich, Kai Stuehler, Tom Luedde, Mirco Castoldi

    MicroRNA miR-122 plays a pivotal role in liver function. Despite numerous studies investigating this miRNA, the global network of genes regulated by miR-122 and its contribution to the underlying pathophysiological mechanisms remain largely unknown. To gain a deeper understanding of miR-122 activity, we employed two complementary approaches. Firstly, through transcriptome analysis of polyribosome-bound RNAs, we discovered that miR-122 exhibits potential antagonistic effects on specific transcription factors known to be dysregulated in liver disease, including nuclear respiratory factor-1 (NRF1) and the E2F transcription factor 4 (E2F4). Secondly, through proteome analysis of hepatoma cells transfected with either miR-122 mimic or antagomir, we discovered changes in several proteins associated with increased malignancy. Interestingly, many of these proteins were reported to be transcriptionally regulated by NRF1 and E2F4, six of which we validated as miR-122 targets. Among these, a negative correlation was observed between miR-122 and glucose-6-phosphate dehydrogenase levels in the livers of patients with hepatitis B virus-associated hepatocellular carcinoma. This study provides novel insights into potential alterations of molecular pathway occurring at the early stages of liver disease, driven by the dysregulation of miR-122 and its associated genes.


  • Open Access

    Differential Modulation of miR-122 Transcription by TGFβ1/BMP6: Implications for Nonresolving Inflammation and Hepatocarcinogenesis

    by Martha Paluschinski, Claus Kordes, Mihael Vucur, Veronika Buettner, Christoph Roderburg, Haifeng C. Xu, Prashant V. Shinte, Philipp A. Lang, Tom Luedde, Mirco Castoldi

    Chronic inflammation is widely recognized as a significant factor that promotes and worsens the development of malignancies, including hepatocellular carcinoma. This study aimed to explore the potential role of microRNAs in inflammation-associated nonresolving hepatocarcinogenesis. By conducting a comprehensive analysis of altered microRNAs in animal models with liver cancer of various etiologies, we identified miR-122 as the most significantly downregulated microRNA in the liver of animals with inflammation-associated liver cancer. Although previous research has indicated the importance of miR-122 in maintaining hepatocyte function, its specific role as either the trigger or the consequence of underlying diseases remains unclear. Through extensive analysis of animals and in vitro models, we have successfully demonstrated that miR-122 transcription is differentially regulated by the immunoregulatory cytokines, by the transforming growth factor-beta 1 (TGFβ1), and the bone morphogenetic protein-6 (BMP6). Furthermore, we presented convincing evidence directly linking reduced miR-122 transcription to inflammation and in chronic liver diseases. The results of this study strongly suggest that prolonged activation of pro-inflammatory signaling pathways, leading to disruption of cytokine-mediated regulation of miR-122, may significantly contribute to the onset and exacerbation of chronic liver disease.


  • Open Access

    Uncovering novel roles of miR-122 in the pathophysiology of the liver: Potential interaction with NRF1 and E2F4 signaling

    by Martha Paluschinski, Jessica Schira-Heinen, Rossella Pellegrino, Lara R. Heij, Jan Bednarsch, Ulf P. Neumann, Thomas Longerich, Kai Stuehler, Tom Luedde, Mirco Castoldi

    MicroRNA miR-122 plays a pivotal role in liver function. Despite numerous studies investigating this miRNA, the global network of genes regulated by miR-122 and its contribution to the underlying pathophysiological mechanisms remain largely unknown. To gain a deeper understanding of miR-122 activity, we employed two complementary approaches. Firstly, through transcriptome analysis of polyribosome-bound RNAs, we discovered that miR-122 exhibits potential antagonistic effects on specific transcription factors known to be dysregulated in liver disease, including nuclear respiratory factor-1 (NRF1) and the E2F Transcription Factor 4 (E2F4). Secondly, through proteome analysis of hepatoma cell transfected with either miR-122 mimic or antagomiR we discovered changes in several proteins associated with increased malignancy. Interestingly, many of these proteins were reported to be transcriptionally regulated by NRF1 and E2F4, six of which we validated as miR-122 targets. Among these, a negative correlation was observed between miR-122 and glucose-6-phosphate dehydrogenase levels in the livers of patients with hepatitis B virus-associated hepatocellular carcinoma. This study provides novel insights into potential alterations of molecular pathway occurring at the early stages of liver disease, driven by the dysregulation of miR-122 and its associated genes.

  • Open Access

    Differential modulation of miR-122 transcription by TGFβ1/BMP6: implications for nonresolving inflammation and hepatocarcinogenesis

    by Martha Paluschinski, Claus Kordes, Mihael Vucur, Veronika Buettner, Christoph Roderburg, Haifeng C Xu, Prashant Shinte, Philipp A Lang, Tom Luedde, Mirco Castoldi

    Chronic inflammation is widely recognized as a significant factor that promotes and worsens the development of malignancies, including hepatocellular carcinoma. This study aimed to explore the potential role of microRNAs in inflammation-associated nonresolving hepatocarcinogenesis. By conducting a comprehensive analysis of altered microRNAs in animal models with liver cancer of various etiologies, we identified miR-122 as the most significantly downregulated microRNA in the liver of animals with inflammation-associated liver cancer. Although previous research has indicated the importance of miR-122 in maintaining hepatocyte function, its specific role as either the trigger or the consequence of underlying diseases remains unclear. Through extensive analysis of animals and in vitro models, we have successfully demonstrated that MIR122 transcription is differentially regulated by the immunoregulatory cytokines by the transforming growth factor-beta 1 (TGFβ1) and the bone morphogenetic protein- 6 (BMP6). Furthermore, we presented convincing evidence directly linking reduced MIR122 transcription to inflammation and in chronic liver diseases. The results of this study strongly suggest that prolonged activation of signaling pathways, leading to disruption of cytokine-mediated regulation of MIR122 , may significantly contribute to the onset and exacerbation of chronic liver disease.